Herbert Helander

Corporate Officer/Principal bei The University of Alabama

Consumer Services

Health Technology

Commercial Services

Profil

Herbert Helander is the founder of Calabar AB, which was founded in 1999.
He held the title of Director at Calabar AB.
Currently, Dr. Helander holds the position of Senior Advisor-Research at AstraZeneca AB, and the position of Professor at both The University of Alabama and the University of California, Berkeley.
Previously, he held the position of Professor at the University of Oklahoma from 2000 to 2012.

Aktive Positionen von Herbert Helander

Unternehmen	Position	Beginn
The University of Alabama	Corporate Officer/Principal	01.12.2009
University of California, Berkeley	Corporate Officer/Principal	01.12.2009
AstraZeneca AB AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.	Corporate Officer/Principal	01.12.2009

Alle aktiven Positionen von Herbert Helander

Ehemalige bekannte Positionen von Herbert Helander

Unternehmen	Position	Ende
University of Oklahoma	Corporate Officer/Principal	-
Calabar AB Calabar AB Medical SpecialtiesHealth Technology Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia, dry mouth. The company develops XALIEVE™ a locally administered formulation of the cholinesterase inhibitor physostigmine, which been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The compound is currently undergoing Phase II repeated dose studies and Calabar is actively looking for partners to take the compound through phase III. For more information contact Business Development. The company is part of the Karolinska Development AB (publ) portfolio.	Gründer	-

Sehen Sie sich die Erfahrung von Herbert Helander im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Herbert Helander im Detail an

Beziehungen

100 +

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	2
Calabar AB Calabar AB Medical SpecialtiesHealth Technology Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia, dry mouth. The company develops XALIEVE™ a locally administered formulation of the cholinesterase inhibitor physostigmine, which been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The compound is currently undergoing Phase II repeated dose studies and Calabar is actively looking for partners to take the compound through phase III. For more information contact Business Development. The company is part of the Karolinska Development AB (publ) portfolio.	Health Technology
AstraZeneca AB AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.	Commercial Services